MedTrace Logo

Losartan to Improve Hip Microfracture

NCT04212650 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2023-10-30

Study results available
· View outcomes & findings →

Summary

Phase I/IIA randomized, double-blind, placebo-controlled clinical trial to assess safety and efficacy of oral losartan for improving cartilage repair following microfracture to treat focal cartilage defects during hip arthroscopy.

Conditions

  • Hip Osteoarthritis
  • Hip Impingement Syndrome
  • Cartilage Damage
  • Fibrosis

Interventions

DRUG

Losartan

Losartan will be administered to improve the quality of hip cartilage repair following arthroscopic microfracture. Losartan is a known anti-fibrotic agent via blocking of TGF-B1.

OTHER

Placebo

Appearance-matched microcrystalline cellulose placebo

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Office of Naval Research (ONR)

    collaborator FED

  • Steadman Philippon Research Institute

    lead OTHER

Principal Investigators

  • Marc J Philippon, MD · Steadman Philippon Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-07
Primary Completion
2020-12-04
Completion
2020-12-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04212650 on ClinicalTrials.gov